A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV).

Trial Profile

A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 May 2015

At a glance

  • Drugs Anthrax immune globulin (Primary) ; Immune globulin
  • Indications Anthrax
  • Focus Adverse reactions
  • Acronyms AIGIV
  • Most Recent Events

    • 07 May 2015 According to an Emergent BioSolutions media release, anthrax immune globulin [Anthrasil] has been approved by the US FDA.
    • 20 May 2010 NCT reports planned patients number as 125.
    • 05 Feb 2010 Planned number of patients changed from 120 to 140 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top